PRSS22

Summary

PRSS22 (serine protease 22, HGNC:14368) is a protein-coding gene on chromosome 16p13.3, encoding Brain-specific serine protease 4 (Q9GZN4). Preferentially cleaves the synthetic substrate H-D-Leu-Thr-Arg-pNA compared to tosyl-Gly-Pro-Arg-pNA.

This gene encodes a member of the trypsin family of serine proteases. The enzyme is expressed in the airways in a developmentally regulated manner. The gene is part of a cluster of serine protease genes on chromosome 16.

Source: NCBI Gene 64063 — RefSeq curated summary.

At a glance

• GWAS associations: 1
• Clinical variants (ClinVar): 54 total
• MANE Select transcript: NM_022119

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:14368
Approved symbol	PRSS22
Name	serine protease 22
Location	16p13.3
Locus type	gene with protein product
Status	Approved
Aliases	hBSSP-4, BSSP-4, SP001LA
Ensembl gene	ENSG00000005001
Ensembl biotype	protein_coding
OMIM	609343
Entrez	64063

Gene structure

Transcript identifiers

Ensembl transcripts: 10 — 4 protein_coding, 3 retained_intron, 2 protein_coding_CDS_not_defined, 1 nonsense_mediated_decay

ENST00000161006, ENST00000570950, ENST00000571228, ENST00000572061, ENST00000574768, ENST00000575164, ENST00000576381, ENST00000577177, ENST00000874724, ENST00000874725

RefSeq mRNA: 1 — MANE Select: NM_022119 NM_022119

CCDS: CCDS10481

Canonical transcript exons

ENST00000161006 — 6 exons

Exon	Start	End
ENSE00001158732	2858023	2858170
ENSE00002671372	2852730	2853329
ENSE00003505840	2855574	2855851
ENSE00003626741	2856822	2856848
ENSE00003663567	2853865	2854022
ENSE00003674823	2856082	2856253

Expression profiles

Bgee: expression breadth ubiquitous, 122 present calls, max score 98.61.

FANTOM5 (CAGE): breadth broad, TPM avg 6.3214 / max 321.6978, expressed in 483 samples.

FANTOM5 promoters (4 alternative TSS)

Promoter ID	TPM avg	Samples expressed
155958	5.3341	411
155957	0.5509	269
155959	0.2461	120
155956	0.1903	102

Top tissues by expression

134 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
lower esophagus mucosa	UBERON:0035834	98.61	gold quality
esophagus mucosa	UBERON:0002469	97.92	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	97.37	gold quality
minor salivary gland	UBERON:0001830	96.93	gold quality
saliva-secreting gland	UBERON:0001044	96.73	gold quality
metanephros cortex	UBERON:0010533	95.73	gold quality
gall bladder	UBERON:0002110	95.03	gold quality
body of pancreas	UBERON:0001150	92.23	gold quality
right uterine tube	UBERON:0001302	90.85	gold quality
prostate gland	UBERON:0002367	89.20	gold quality
pancreas	UBERON:0001264	88.56	gold quality
tonsil	UBERON:0002372	88.03	gold quality
vagina	UBERON:0000996	87.36	gold quality
right lobe of thyroid gland	UBERON:0001119	86.52	gold quality
left lobe of thyroid gland	UBERON:0001120	85.65	gold quality
thyroid gland	UBERON:0002046	84.95	gold quality
pituitary gland	UBERON:0000007	84.09	gold quality
mucosa of stomach	UBERON:0001199	83.42	gold quality
upper lobe of left lung	UBERON:0008952	83.32	gold quality
body of stomach	UBERON:0001161	83.24	gold quality
islet of Langerhans	UBERON:0000006	83.16	gold quality
skin of abdomen	UBERON:0001416	82.04	gold quality
adenohypophysis	UBERON:0002196	82.02	gold quality
placenta	UBERON:0001987	82.00	gold quality
adult mammalian kidney	UBERON:0000082	81.38	gold quality
right lung	UBERON:0002167	80.83	gold quality
stomach	UBERON:0000945	80.04	gold quality
lung	UBERON:0002048	79.83	gold quality
urinary bladder	UBERON:0001255	79.73	gold quality
zone of skin	UBERON:0000014	79.56	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	12.92

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

42 targeting PRSS22, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-4500	99.99	72.72	2367
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-4531	99.99	69.70	3181
HSA-LET-7A-5P	99.98	72.29	1790
HSA-LET-7B-5P	99.98	72.31	1790
HSA-LET-7C-5P	99.98	72.29	1790
HSA-LET-7E-5P	99.98	72.29	1790
HSA-LET-7F-5P	99.98	72.56	1784
HSA-LET-7G-5P	99.98	72.37	1784
HSA-LET-7I-5P	99.98	72.37	1788
HSA-MIR-98-5P	99.98	72.33	1787
HSA-LET-7D-5P	99.96	71.76	1632
HSA-MIR-4458	99.96	71.64	1650
HSA-MIR-3143	99.93	71.96	3104
HSA-MIR-6721-5P	99.93	68.92	2981
HSA-MIR-765	99.84	68.24	2442
HSA-MIR-11181-3P	99.75	66.38	2205
HSA-MIR-4729	99.69	72.18	4233
HSA-MIR-766-5P	99.47	67.91	2225
HSA-MIR-32-3P	99.36	68.20	2517
HSA-MIR-5100	99.11	67.52	1098
HSA-MIR-6894-5P	98.70	63.78	809
HSA-MIR-6831-5P	98.26	67.20	990
HSA-MIR-4443	98.02	66.25	1928
HSA-MIR-299-3P	97.73	66.67	773
HSA-MIR-3927-3P	97.68	66.76	892
HSA-MIR-7154-3P	97.65	65.02	985
HSA-MIR-6787-5P	97.54	63.85	457

Literature-anchored findings (GeneRIF, showing 3)

• Tryptase epsilon also was able to induce pro-uPA-expressing smooth muscle cells to increase their migration (PMID:15701722)
• prosemin is a novel serine protease of the chromosome 16 cluster that is highly expressed in the pancreas. (PMID:16176265)
• Our findings collectively support a potential role of T3 in cancer cell progression through regulation of the BSSP4 protease via the ERK 1/2-C/EBPbeta-VEGF cascade (PMID:24980078)

Cross-species orthologs

10 orthologs

Organism	Symbol	Gene ID
danio_rerio	st14b	ENSDARG00000044655
danio_rerio	st14a	ENSDARG00000061173
danio_rerio		ENSDARG00000062758
danio_rerio	tmprss15	ENSDARG00000079393
mus_musculus	Prss22	ENSMUSG00000045027
rattus_norvegicus	Prss22	ENSRNOG00000039698
drosophila_melanogaster	Sb	FBGN0003319
drosophila_melanogaster	CG1632	FBGN0030027
drosophila_melanogaster	CG10587	FBGN0037039
drosophila_melanogaster	CG17242	FBGN0250841

Paralogs (17): PRSS21 (ENSG00000007038), TMPRSS11E (ENSG00000087128), HPN (ENSG00000105707), TMPRSS13 (ENSG00000137747), ST14 (ENSG00000149418), TMPRSS11D (ENSG00000153802), TMPRSS15 (ENSG00000154646), TMPRSS3 (ENSG00000160183), TMPRSS5 (ENSG00000166682), TMPRSS7 (ENSG00000176040), TMPRSS9 (ENSG00000178297), TMPRSS2 (ENSG00000184012), TMPRSS11B (ENSG00000185873), TMPRSS6 (ENSG00000187045), TMPRSS11A (ENSG00000187054), TMPRSS11F (ENSG00000198092), PRSS41 (ENSG00000215148)

Protein

Protein identifiers

Brain-specific serine protease 4 — Q9GZN4 (reviewed: Q9GZN4)

Alternative names: Serine protease 22, Serine protease 26, Tryptase epsilon

All UniProt accessions (3): Q9GZN4, I3L116, I3L147

UniProt curated annotations — full annotation on UniProt →

Function. Preferentially cleaves the synthetic substrate H-D-Leu-Thr-Arg-pNA compared to tosyl-Gly-Pro-Arg-pNA.

Subcellular location. Secreted.

Tissue specificity. Expressed abundantly in the epithelial cells of the airways, including trachea, esophagus and fetal lung. Scarce in adult lung. Expressed at low levels in placenta, pancreas, prostate and thyroid gland.

Similarity. Belongs to the peptidase S1 family.

RefSeq proteins (1): NP_071402* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001254	Trypsin_dom	Domain
IPR001314	Peptidase_S1A	Family
IPR009003	Peptidase_S1_PA	Homologous_superfamily
IPR018114	TRYPSIN_HIS	Active_site
IPR033116	TRYPSIN_SER	Active_site
IPR043504

Pfam: PF00089

UniProt features (11 total): disulfide bond 4, active site 3, signal peptide 1, chain 1, domain 1, glycosylation site 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9GZN4-F1	86.65	0.70

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (3): 90 (charge relay system); 141 (charge relay system); 242 (charge relay system)

Disulfide bonds (4): 238–266, 75–91, 175–248, 208–227

Glycosylation sites (1): 70

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 0 (showing top):

GO Biological Process (2): proteolysis (GO:0006508), positive regulation of peptidase activity (GO:0010952)

GO Molecular Function (6): serine-type endopeptidase activity (GO:0004252), serine-type peptidase activity (GO:0008236), peptidase activator activity (GO:0016504), protein binding (GO:0005515), peptidase activity (GO:0008233), hydrolase activity (GO:0016787)

GO Cellular Component (3): obsolete extracellular space (GO:0005615), extracellular region (GO:0005576), membrane (GO:0016020)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
peptidase activity	3
cellular anatomical structure	2
protein metabolic process	1
positive regulation of proteolysis	1
positive regulation of hydrolase activity	1
regulation of peptidase activity	1
endopeptidase activity	1
serine-type peptidase activity	1
serine hydrolase activity	1
enzyme activator activity	1
peptidase regulator activity	1
binding	1
hydrolase activity	1
catalytic activity, acting on a protein	1
catalytic activity	1

Protein interactions and networks

STRING

880 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
PRSS22	PRR23A	A6NEV1	475
PRSS22	KCNU1	A8MYU2	438
PRSS22	OR6C1	Q96RD1	438
PRSS22	CFAP144	A6NL82	399
PRSS22	TESPA1	A2RU30	394
PRSS22	ADCY5	O95622	353
PRSS22	FGF5	P12034	353
PRSS22	CYP2S1	Q96SQ9	353
PRSS22	EDN3	P14138	350
PRSS22	BCAT1	P54687	343
PRSS22	LIPE	Q05469	337
PRSS22	PURG	Q9UJV8	334
PRSS22	ZNF319	Q9P2F9	333
PRSS22	IAH1	Q2TAA2	321
PRSS22	TMEM69	Q5SWH9	310

IntAct

5 interactions, top by confidence:

A	B	Type	Score
PRSS22	PPM1A	psi-mi:“MI:0915”(physical association)	0.560
PRSS22	PPM1A	psi-mi:“MI:0914”(association)	0.560
SSUH2	IGLC7	psi-mi:“MI:0914”(association)	0.350

BioGRID (17): XIAP (Affinity Capture-MS), PPM1A (Affinity Capture-MS), PPM1A (Affinity Capture-MS), PPM1A (Affinity Capture-MS), DDX19B (Affinity Capture-MS), GALNT1 (Affinity Capture-MS), HSPA13 (Affinity Capture-MS), PCDH1 (Affinity Capture-MS), TUBA1A (Affinity Capture-MS), SORL1 (Affinity Capture-MS), LRRC1 (Affinity Capture-MS), CTPS2 (Affinity Capture-MS), TCP11L1 (Affinity Capture-MS), GPR107 (Affinity Capture-MS), PRSS22 (Affinity Capture-MS)

ESM2 similar proteins: A1L453, A2VE36, A6NIE9, A8MTI9, E5RG02, O35453, O70169, P08709, P20231, P21845, P50343, P83748, Q14B25, Q14BX2, Q15661, Q16651, Q2F9P2, Q2F9P4, Q2UVH8, Q3UKY7, Q3V0Q7, Q402U7, Q571E5, Q5FBW1, Q5FBW2, Q5M8S2, Q6AXZ6, Q6BEA2, Q6IE62, Q6IE63, Q6UWB4, Q76HL1, Q7RTY5, Q7Z410, Q7Z5A4, Q8BJR6, Q8K4I7, Q8VIF2, Q920S2, Q99MS4

Diamond homologs: A0A126GUP6, A0A182C2Z2, A0A1S4H5M5, A8JUP7, B5U2W0, B7YZU2, F5HKX0, O15393, O35453, O60235, O60259, O97366, P00774, P03951, P03952, P05049, P05981, P08419, P09871, P10323, P13582, P14272, P21902, P23578, P25155, P26262, P28175, P29293, P31394, P33587, P35035, P35036, P35037, P35039, P35041, P35045, P35046, P35047, P40313, P48038

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

54 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	47
Likely benign	3
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

1387 predictions. Top by Δscore:

Variant	Effect	Δscore
16:2853326:CGCC:C	acceptor_gain	1.0000
16:2853328:CC:C	acceptor_gain	1.0000
16:2853329:CC:C	acceptor_gain	1.0000
16:2853330:C:CA	acceptor_loss	1.0000
16:2853911:T:TA	donor_gain	1.0000
16:2854018:GGGAA:G	acceptor_gain	1.0000
16:2854019:GGAA:G	acceptor_gain	1.0000
16:2854020:GAA:G	acceptor_gain	1.0000
16:2854021:AA:A	acceptor_gain	1.0000
16:2854023:C:CC	acceptor_gain	1.0000
16:2855852:C:CC	acceptor_gain	1.0000
16:2856080:A:AC	donor_gain	1.0000
16:2856080:ACT:A	donor_gain	1.0000
16:2856081:C:CC	donor_gain	1.0000
16:2856081:CT:C	donor_gain	1.0000
16:2856081:CTC:C	donor_gain	1.0000
16:2856083:C:CA	donor_gain	1.0000
16:2856253:AC:A	acceptor_loss	1.0000
16:2856254:C:CC	acceptor_gain	1.0000
16:2858018:CGTA:C	donor_loss	1.0000
16:2858019:GTAC:G	donor_loss	1.0000
16:2858020:TACCT:T	donor_loss	1.0000
16:2858021:A:T	donor_loss	1.0000
16:2853325:TCGCC:T	acceptor_gain	0.9900
16:2853326:CGCCC:C	acceptor_gain	0.9900
16:2853330:C:CC	acceptor_gain	0.9900
16:2853858:AGCTC:A	donor_loss	0.9900
16:2853859:GCTCA:G	donor_loss	0.9900
16:2853860:CTCAC:C	donor_loss	0.9900
16:2853861:TCA:T	donor_loss	0.9900

AlphaMissense

2028 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
16:2855593:C:A	W180C	0.996
16:2855593:C:G	W180C	0.996
16:2853902:C:G	C227S	0.994
16:2853903:A:T	C227S	0.994
16:2853195:C:A	W284C	0.992
16:2853195:C:G	W284C	0.992
16:2855706:C:G	A143P	0.992
16:2856176:A:G	W63R	0.992
16:2856176:A:T	W63R	0.992
16:2856174:C:A	W63C	0.990
16:2856174:C:G	W63C	0.990
16:2853959:C:G	C208S	0.988
16:2853960:A:T	C208S	0.988
16:2855595:A:G	W180R	0.988
16:2855595:A:T	W180R	0.988
16:2853264:G:C	S261R	0.987
16:2853264:G:T	S261R	0.987
16:2853266:T:G	S261R	0.987
16:2853304:C:G	C248S	0.987
16:2853305:A:T	C248S	0.987
16:2853310:A:G	L246P	0.987
16:2856090:A:C	C91W	0.986
16:2853899:G:T	A228D	0.985
16:2853989:A:G	L198P	0.985
16:2855608:G:C	C175W	0.985
16:2855705:G:T	A143D	0.985
16:2856133:C:T	G77D	0.985
16:2856139:C:G	C75S	0.985
16:2856140:A:T	C75S	0.985
16:2853903:A:G	C227R	0.984

dbSNP variants (sampled 300 via entrez): RS1000000957 (16:2859525 C>T), RS1000036132 (16:2859310 C>G), RS1000268685 (16:2853518 T>C), RS1000508984 (16:2853754 G>A,C,T), RS1001326724 (16:2854415 G>A,C,T), RS1001380654 (16:2854102 C>A,G,T), RS1001480613 (16:2858694 C>T), RS1001874520 (16:2853010 A>C,G), RS1002487661 (16:2854688 T>C), RS1003054140 (16:2855494 C>T), RS1003272652 (16:2857945 A>C), RS1003850294 (16:2858953 C>A,T), RS1004002050 (16:2853078 G>A,C), RS1004110761 (16:2858734 C>G), RS1004354535 (16:2853337 G>A,T)

Disease associations

OMIM: gene MIM:609343 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): prostate cancer (MONDO:0008315)

Orphanet (1): Familial prostate cancer (Orphanet:1331)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST006585_564	Blood protein levels	4.000000e-24

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D011471	Prostatic Neoplasms	C04.588.945.440.770; C12.100.500.260.750; C12.100.500.565.625; C12.200.294.260.750; C12.200.294.565.625; C12.200.758.409.750; C12.900.619.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

26 total (human), top 26 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Benzo(a)pyrene	affects methylation, decreases methylation, increases expression	3
sodium arsenite	increases abundance, increases expression	2
Calcitriol	increases expression, affects cotreatment	2
Silicon Dioxide	increases expression	2
Tobacco Smoke Pollution	affects expression, increases expression	2
aristolochic acid I	increases expression	1
sotorasib	affects cotreatment, decreases expression	1
testosterone enanthate	affects expression	1
bisphenol A	affects methylation	1
ethyl-p-hydroxybenzoate	increases expression	1
beta-lapachone	increases expression	1
tris(1,3-dichloro-2-propyl)phosphate	increases expression	1
2,2’,4,4’-tetrabromodiphenyl ether	increases expression	1
trametinib	affects cotreatment, decreases expression	1
(+)-JQ1 compound	decreases expression	1
NVP-BKM120	affects cotreatment, decreases expression	1
Resveratrol	affects cotreatment, decreases expression	1
Arsenic	increases abundance, increases expression	1
Diethylhexyl Phthalate	increases expression	1
Estradiol	affects cotreatment, decreases expression	1
Plant Extracts	decreases expression, affects cotreatment	1
Testosterone	affects cotreatment, increases expression	1
Valproic Acid	increases methylation	1
Cadmium Chloride	increases expression	1
Vitamin K 3	affects expression	1
Particulate Matter	increases expression	1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00029224	PHASE4	COMPLETED	Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
NCT00035997	PHASE4	COMPLETED	Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis
NCT00063609	PHASE4	COMPLETED	The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy
NCT00103623	PHASE4	SUSPENDED	The Plenaxis® Experience Study
NCT00106392	PHASE4	COMPLETED	A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy
NCT00185029	PHASE4	UNKNOWN	MR-Lymphography and Lymph Node Staging in Prostate Cancer
NCT00199485	PHASE4	COMPLETED	Angelica Sinensis for the Treatment of Hot Flashes in Men Undergoing LHRH Therapy for Prostate Cancer
NCT00219219	PHASE4	COMPLETED	Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases
NCT00219271	PHASE4	COMPLETED	Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer
NCT00237146	PHASE4	COMPLETED	Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy
NCT00242554	PHASE4	COMPLETED	Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases
NCT00280098	PHASE4	COMPLETED	Docetaxel in the Treatment of Hormone Refractory Prostate Cancer
NCT00293696	PHASE4	COMPLETED	Casodex/Zoladex Biomarkers in Localised Prostate Cancer
NCT00334139	PHASE4	COMPLETED	Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer
NCT00375765	PHASE4	COMPLETED	Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer
NCT00391690	PHASE4	COMPLETED	Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer
NCT00422708	PHASE4	COMPLETED	Local Anesthesia for Prostate Biopsy
NCT00526331	PHASE4	COMPLETED	Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy
NCT00590213	PHASE4	COMPLETED	Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX
NCT00629330	PHASE4	TERMINATED	Dissemination of Prostate Cancer Screening to PCP’s in African American Communities
NCT00771966	PHASE4	COMPLETED	Radical Prostatectomy and Perioperative Fluid Therapy
NCT00805701	PHASE4	COMPLETED	Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation
NCT00859027	PHASE4	COMPLETED	Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer
NCT00906269	PHASE4	UNKNOWN	Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer
NCT00953277	PHASE4	COMPLETED	Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer
NCT00982800	PHASE4	COMPLETED	Does Postoperative Gabapentin Reduce Pain, Opioid Consumption and Anxiety and Have a Positive Effect on Health Related Quality of Life After Radical Prostatectomy?
NCT01083199	PHASE4	COMPLETED	Global Performance Evaluation of the AMS CONTINUUM™ Device
NCT01136226	PHASE4	COMPLETED	Evaluate Recovery of Testosterone for Patients Using Eligard
NCT01161563	PHASE4	COMPLETED	Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration
NCT01230905	PHASE4	COMPLETED	Study to Monitor the Effects of Androgen Suppression Treatment on the Heart
NCT01296672	PHASE4	COMPLETED	3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer
NCT01365143	PHASE4	TERMINATED	Prospective Randomized Trial Comparing Robotic Versus Open Radical Prostatectomy
NCT01379742	PHASE4	UNKNOWN	Comparison of Between ThinSeed™ and OncoSeed™ for Permanent Prostate Brachytherapy
NCT01486563	PHASE4	COMPLETED	Hydroxyethyl Starch and Renal Function After Radical Prostatectomy
NCT01511874	PHASE4	COMPLETED	Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer
NCT01512472	PHASE4	TERMINATED	Firmagon (Degarelix) Intermittent Therapy
NCT01547416	PHASE4	COMPLETED	The Effect of Combined General/Epidural Anesthesia Versus General Anesthesia on Diaphragmatic Function
NCT01571544	PHASE4	COMPLETED	The Use of Thermal Suits as Preventing Hypothermia During Surgery
NCT01581749	PHASE4	UNKNOWN	Evaluation of Truebeam for Low-Intermediate Risk Prostate Cancer
NCT01649635	PHASE4	COMPLETED	Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer